Deerfield

View All

Deerfield Dana Farber Deal FDA Nod to BMS Breyanzi & TG Ukoniq
Deerfield/ Dana-Farber’s USD 130 Million Cancer Research Deal; FDA-Approval to BMS’ Breyanzi & TG Therapeutics’ Ukoniq; EU Marketing Rights for ViiV Healthcare’s Rukobia

Deerfield and Dana-Farber Establish Links in USD 130 Million Cancer Research Deal  Deerfield Management has entered into a research agreement with Dana-Farber Cancer Institute to fuel the development of therapeutics and diagnostics for cancer. The move came not long after healthcare investor giant Deerfield...

Find More

Business cocktail 25 april
GSK to spend $100M; Lilly sell; Sherlock Bio raises $31M; Deerfield, UIC to foster research

GSK to spend USD 100 M to boost its vaccine production Drug maker GlaxoSmithKline has announced to invest USD100 million in its vaccine production site in Montana-one of its nine manufacturing units in the USA. In order to cope with the supply issues GSK faced last year, the company wishes to boost its vaccine p...

Find More

Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates; Celgene’s deal

Preclinical biotech Synthorx needs a USD 100 Million IPO The early-stage Synthorx needs USD 100 million IPO.  A while ago, La Jolla, California-based biotech got off a USD 63 million series C, but now wants a USD 100 million from an IPO to progress its pipelines of synthetic cytokines, which are designed to improve ...

Find More